We are happy to announce that Cromos™ Pharma will participate in the 11th DIA China Annual Meeting 2019 which takes place on 20-23 May 2019 in Beijing, China.
The DIA China Annual Meeting 2019 will bring together 3000+ pharmaceutical R&D professionals from different continents and regions, involved at all levels of the health care product development spectrum, to discuss recent and upcoming transformational changes for China’s innovation and regulatory environments. DIA China 2019 boasts more than 120 exhibiting companies, over 14+ themes, more than 80 sessions and explorable networking opportunities.
Cromos Pharma is a premier mid-sized CRO with strong presence in US, Central & Eastern Europe, Post-Soviet regions. The company provides a full spectrum of trial-related services which includes regulatory consulting and compliance, medical writing, enrollment feasibility assessments, monitoring, project management, warehousing/logistics, data management and biostatistics. We are experts in a rapid recruitment of patients in a variety of therapeutic areas, having performed a multitude of clinical programs of different stages and sizes. As an example, we are currently running a breast cancer biosimilar study in which the first patient in Eastern Europe was enrolled within less than 3 months after protocol finalization, and all the targeted 502 patients in 52 sites from 6 countries were enrolled within 6.5 months after the first patient in.
We look forward to having a talk to you and discussing how Cromos Pharma can support your clinical trials in US, Central & Eastern Europe, Post-Soviet regions. Whether you need end to end services or just enrollment support, we encourage you to meet our team. Please contact directly Tatiana
, BD Director, to arrange a meeting.